RLAY - Relay Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
RLAY price evolution
RLAY
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $136.83 | $155.57 | $146.44 | |
| Short term investments | $554.29 | $596.74 | $606.35 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $865.13 | $704.27 | $770.1 | $770.1 |
| Long term investments | ||||
| Property, plant & equipment | $60.57 | $63.27 | $66.33 | $68.87 |
| Goodwill & intangible assets | $2.3 | $2.3 | $2.3 | |
| Total noncurrent assets | $68.28 | $71.34 | $73.88 | |
| Total investments | $554.29 | $596.74 | $606.35 | |
| Total assets | $930.12 | $772.55 | $841.44 | $843.98 |
| Current liabilities | ||||
| Accounts payable | $6.87 | $11.17 | $7.97 | $9.21 |
| Deferred revenue | ||||
| Short long term debt | $5.33 | $5.15 | $4.96 | |
| Total current liabilities | $46.97 | $45.04 | $37.14 | $30.27 |
| Long term debt | $45.76 | $47.16 | $48.5 | |
| Total noncurrent liabilities | $45.76 | $58.53 | $61.71 | |
| Total debt | $51.1 | $52.31 | $53.47 | |
| Total liabilities | $91.25 | $90.81 | $95.68 | $91.98 |
| Shareholders' equity | ||||
| Retained earnings | -$1662.29 | -$1574.18 | -$1481.97 | -$1400.58 |
| Other shareholder equity | $2.51 | -$1.34 | -$1.16 | -$0.2 |
| Total shareholder equity | $681.74 | $745.76 | $752 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $146.44 | $154.37 | $282.7 | $448.52 |
| Short term investments | $606.35 | $847.12 | $677.95 | $230.41 |
| Net receivables | $5.22 | $0.4 | $75 | |
| Inventory | ||||
| Total current assets | $770.1 | $1019.5 | $976.24 | $770.1 |
| Long term investments | ||||
| Property, plant & equipment | $68.87 | $75.39 | $27.32 | $28.83 |
| Goodwill & intangible assets | $2.3 | $2.3 | $2.3 | |
| Total noncurrent assets | $73.88 | $80.27 | $32.2 | $29.73 |
| Total investments | $606.35 | $847.12 | $677.95 | $230.41 |
| Total assets | $843.98 | $1099.77 | $1008.44 | $799.83 |
| Current liabilities | ||||
| Accounts payable | $9.21 | $10.58 | $8.28 | $6.35 |
| Deferred revenue | $0.25 | |||
| Short long term debt | $4.96 | $4.28 | $1.84 | $1.52 |
| Total current liabilities | $30.27 | $63.71 | $24.32 | $13.63 |
| Long term debt | $48.5 | $53.47 | $21.06 | $22.9 |
| Total noncurrent liabilities | $61.71 | $85.84 | $86.31 | $22.9 |
| Total debt | $53.47 | $57.74 | $22.9 | $24.42 |
| Total liabilities | $91.98 | $149.55 | $110.64 | $36.54 |
| Shareholders' equity | ||||
| Retained earnings | -$1400.58 | -$1058.61 | -$768.1 | -$404.23 |
| Other shareholder equity | -$0.2 | -$10.42 | -$1.09 | $0.06 |
| Total shareholder equity | $752 | $950.22 | $897.81 | $763.29 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.01 | -$0 | ||
| Cost of revenue | ||||
| Gross Profit | $10.01 | -$0 | ||
| Operating activities | ||||
| Research & development | $91.99 | $82.4 | $77.5 | |
| Selling, general & administrative | $20.14 | $19.8 | $16.77 | |
| Total operating expenses | $96.37 | $112.13 | $102.2 | $94.26 |
| Operating income | -$112.13 | -$92.19 | -$94.26 | |
| Income from continuing operations | ||||
| EBIT | -$92.21 | -$81.39 | -$83.5 | |
| Income tax expense | ||||
| Interest expense | $8.27 | |||
| Net income | ||||
| Net income | -$88.11 | -$92.21 | -$81.39 | -$83.5 |
| Income (for common shares) | -$92.21 | -$81.39 | -$83.5 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $25.55 | $1.38 | $3.03 | $82.65 |
| Cost of revenue | ||||
| Gross Profit | $25.55 | $1.38 | $3.03 | $82.65 |
| Operating activities | ||||
| Research & development | $330.02 | $246.35 | $172.65 | $99.86 |
| Selling, general & administrative | $74.95 | $65.98 | $57.39 | $38.59 |
| Total operating expenses | $404.97 | $312.33 | $364.89 | $138.45 |
| Operating income | -$379.42 | -$310.95 | -$361.86 | -$55.8 |
| Income from continuing operations | ||||
| EBIT | -$341.97 | -$290.51 | -$363.87 | -$52.41 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$341.97 | -$290.51 | -$363.87 | -$52.41 |
| Income (for common shares) | -$341.97 | -$290.51 | -$363.87 | -$230.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$92.21 | -$81.39 | -$83.5 | |
| Operating activities | ||||
| Depreciation | $1.37 | $1.4 | $1.38 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $26.83 | $27.19 | $19.27 | |
| Total cash flows from operations | -$65.83 | -$50.32 | -$89.19 | |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$1.78 | -$0.12 | |
| Investments | $45.56 | $12.31 | $59.8 | |
| Total cash flows from investing | -$70.08 | $45.55 | $10.53 | $59.68 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.54 | $48.92 | $21.92 | |
| Net borrowings | ||||
| Total cash flows from financing | $269.35 | $1.54 | $48.92 | $21.92 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $8.03 | -$18.74 | $9.13 | -$7.59 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$341.97 | -$290.51 | -$363.87 | -$52.41 |
| Operating activities | ||||
| Depreciation | $5.27 | $4.13 | $3.92 | $3.55 |
| Business acquisitions & disposals | -$25.3 | |||
| Stock-based compensation | $86.03 | $56.14 | $48.45 | $31.96 |
| Total cash flows from operations | -$300.32 | -$229.49 | -$74.41 | -$102.49 |
| Investing activities | ||||
| Capital expenditures | -$4.13 | -$9.06 | -$3.47 | -$1.93 |
| Investments | $261.76 | -$179.68 | -$450.74 | $83.6 |
| Total cash flows from investing | $257.63 | -$188.75 | -$479.51 | $81.67 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $34.75 | $289.91 | $388.09 | $429.02 |
| Net borrowings | ||||
| Total cash flows from financing | $34.75 | $289.91 | $388.09 | $426.51 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.93 | -$128.32 | -$165.83 | $405.69 |
News
Fundamentals
| Market cap | $333.77M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 166.89M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$345.20M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.97 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.07 |
|---|---|
| ROA | -40.75% |
| ROE | N/A |
| Debt/Equity | 0.12 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 18.42 |
| Quick ratio | N/A |